Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wagner Adds Germany To Role As Stada Simplifies Structure

Eelco Ockers Departs Company As Stada Streamlines Organizational Structure

Executive Summary

Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

You may also be interested in...



People On The Move: Appointments At Stada, CHPA, Valbiotis And DSA

The latest global health and wellness industry appointments: Stada hires Uriach's Roura to lead Spanish OTC business; CHPA elects J&J's Goodridge; Valbiotis brings in Ipsen's Bessy; and Mannatech's Bala joins DSA's board.

Stada Launches Medical Cannabis Portfolio

Stada has announced the launch of its medical cannabis portfolio under the brand CannabiStada in Germany. The company will be rolling out both flowers and whole extracts, primarily geared towards chronic pain patients for whom established medications, such as opioids, do not work.

Who’s Hired? Stada Names New Specialty Head

Stada has appointed a new specialty head who will have global responsibility for the firm’s biosimilars business. Meanwhile, Hyloris has named a new business development chief and a generics industry veteran has joined Slayback’s board.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150988

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel